TWiV provides an update on hepatitis of unknown etiology in children, an experimental nanoparticle vaccine for Epstein-Barr virus, and minimal impact of bamlanivimab therapy on antiviral antibodies induced by vaccination.
In COVID-19 clinical update #49, Daniel Griffin discusses CDC guidelines on mask use, drop in test frequency in the US, resurgence of COVID-19 in Brazil, possible impact of Pfizer vaccine on viral load, EUA for bamlanivimab and etesevimab administered together, and preliminary results of Tocilizumab in hospitalized patients.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Dickson D.
Despommier, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Jolene Ramsey, Ph.D.